Literature DB >> 32604398

Ibuprofen versus acetazolamide for prevention of acute mountain sickness.

Maximilian Schilling1, Sebastián Irarrázaval2.   

Abstract

INTRODUCTION: Acute mountain sickness is a common condition occurring in healthy subjects that undergo rapid ascent without prior acclimatization, as low as 2500 meters above sea level. The classic preventive agent has been acetazolamide, although in the last decade there has been evidence favoring ibuprofen. However, it is unclear which method is more efficient.
METHODS: We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis) and generated a summary of findings table using the GRADE approach. RESULTS AND
CONCLUSIONS: We identified two systematic reviews that included only one primary study, which is a randomized trial. We concluded it is not possible to establish whether ibuprofen is better or worse than acetazolamide because the certainty of evidence has been evaluated as very low.

Entities:  

Keywords:  Epistemonikos; GRADE.; NSAIDs; acetazolamide; high altitude illness; ibuprofen; Acute mountain sickness

Mesh:

Substances:

Year:  2020        PMID: 32604398     DOI: 10.5867/medwave.2020.05.7732

Source DB:  PubMed          Journal:  Medwave        ISSN: 0717-6384


  2 in total

Review 1.  High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention.

Authors:  Martin Burtscher; Urs Hefti; Jacqueline Pichler Hefti
Journal:  Sports Med Health Sci       Date:  2021-04-16

2.  Prophylaxis of ibuprofen in acute mountain sickness: A protocol for systematic review and meta-analysis.

Authors:  Hai Yi; Kuiying Wang; Xinyu Gan; Li Li; Qian Zhang; Jiao Xiang; Xiuwei Yuan; Yugang Zhang; Yonghua Wang
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.